Use of pressurized metered dose inhalers in patients with chronic obstructive pulmonary disease: review of evidence

References

• Montuschi P. Drugs for chronic obstructive pulmonary disease. Curr Med Chem 2013;20(12):1461-3
   PubMed Web of Science ®Google Scholar
• Montuschi P. Pharmacological treatment of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2006;1(4):409-23
   PubMedGoogle Scholar
• Fuso L, Mores N, Valente S, et al. Long-acting beta-agonists and their association with inhaled corticosteroids in COPD. Curr Med Chem 2013;20(12):1477-95
   PubMed Web of Science ®Google Scholar
• Plaza V, Sanchis J. Medical personnel and patient skill in the use of metered dose inhalers: a multicentric study. CESEA Group. Respiration 1998;65(3):195-8
   PubMed Web of Science ®Google Scholar
• Lavorini F, Magnan A, Dubus JC, et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med 2008;102(4):593-604
   PubMed Web of Science ®Google Scholar
• Wieshammer S, Dreyhaupt J. Dry powder inhalers: which factors determine the frequency of handling errors? Respiration 2008;75(1):18-25
   PubMed Web of Science ®Google Scholar
• Rees J. Methods of delivering drugs. BMJ 2005;331(7515):504-6
   PubMedGoogle Scholar
• Brennan VK, Osman LM, Graham H, et al. True device compliance: the need to consider both competence and contrivance. Respir Med 2005;99(1):97-102
   PubMed Web of Science ®Google Scholar
• Brocklebank D, Ram F, Wright J, et al. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. Health Technol Assess 2001;5(26):1-149
   PubMedGoogle Scholar
• Vincken W, Dekhuijzen PNR, Barnes P. ADMIT Group. The ADMIT series – issues in inhalation therapy. 4) How to choose inhaler devices for the treatment of COPD. Prim Care Respir J 2010;19(1):10-20
   PubMedGoogle Scholar
• Al-Showair AM, Tarsin WY, Assi KH, et al. Can all patients with COPD use the correct inhalation flow with all inhalers and does training help? Respir Med 2007;101(11):2395-401
   PubMed Web of Science ®Google Scholar
• Barry PW, O’Callaghan C. Inhalational drug delivery from 7 different spacer devices. Thorax 1996;51(8):835-40
   PubMed Web of Science ®Google Scholar
• Dekhuijzen PNR, Vincken W, Virchow JC, et al. Prescription of inhalers in asthma and COPD: towards a rational, rapid and effective approach. Respir Med 2013;107(12):1817-21
   PubMed Web of Science ®Google Scholar
• Ram FS, Brocklebank DM, Muers M, et al. Pressurised metered-dose inhalers versus all other hand-held inhalers devices to deliver bronchodilators for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002(1):CD002170
   PubMedGoogle Scholar
• Ramlal SK, Visser FJ, Hop WC, et al. The effect of bronchodilators administered via aerochamber or a nebulizer on inspiratory lung function parameters. Respir Med 2013;107(9):1393-9
   Google Scholar
• Sheth K, Wasserman RL, Lincourt WR, et al. Fluticasone propionate/salmeterol hydrofluoroalkane via metered-dose inhaler with integrated dose counter: performance and patient satisfaction. Int J Clin Pract 2006;60(10):1218-24
   PubMed Web of Science ®Google Scholar
• Wasserman RL, Sheth K, Lincourt WR, et al. Real-world assessment of a metered-dose inhaler with integrated dose counter. Allergy Asthma Proc 2006;27(6):486-92
   PubMed Web of Science ®Google Scholar
• Eiser NM, Phillips C, Wooler PA. Does the mode of inhalation affect the bronchodilator response in patients with severe COPD? Respir Med 2001;95(6):476-83
   Google Scholar
• Turner JR, Corkery KJ, Eckman D, et al. Equivalence of continuous flow nebulizer and metered-dose inhaler with reservoir bag for treatment of acute airflow obstruction. Chest 1988;93(3):476-81
   PubMed Web of Science ®Google Scholar
• Woods JA, Usery JB, Self TH, Finch CK. An evaluation of inhaled bronchodilator therapy in patients hospitalized for non-life-threatening COPD exacerbations. South Med J 2011;104(11):742-5
   Google Scholar
• Guss D, Barash IA, Castillo EM. Characteristics of spacer device use by patients with asthma and COPD. J Emerg Med 2008;35(4):357-61
   Google Scholar
• Tronde A, Gillen M, Borgström L, et al. Pharmacokinetics of budesonide and formoterol administered via one pressurized metered-dose inhaler in patients with asthma and COPD. J Clin Pharmacol 2008;48(11):1300-8
   Google Scholar
• Kosoglou T, Hubbell J, Xuan F, et al. Comparison of the systemic bioavailability of mometasone furoate after oral inhalation from a mometasone furoate/formoterol fumarate metered-dose inhaler versus a mometasone furoate dry-powder inhaler in patients with chronic obstructive pulmonary. Int J Chron Obstruct Pulmon Dis 2013;8:107-16
   Web of Science ®Google Scholar
• Brusasco V, Canonica GW, Dal Negro R, et al. Formoterol by pressurized metered-dose aerosol or dry powder on airway obstruction and lung hyperinflation in partially reversible COPD. J Aerosol Med Pulm Drug Deliv 2011;24(5):235-43
   PubMed Web of Science ®Google Scholar
• Brashier B, Dhembare P, Jantikar A, et al. Tiotropium administered by a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator response as that administered by a Rotahaler in adult subjects with stable moderate-to-severe COPD. Respir Med 2007;101(12):2464-71
   PubMed Web of Science ®Google Scholar
• Terzano C, Petroianni A, Ricci A, Allegra L. Combination therapy in COPD: different response of COPD stages and predictivity of functional parameters. Eur Rev Med Pharmacol Sci 2005;9(4):209-15
   Google Scholar
• Koser A, Westerman J, Sharma S, et al. Safety and efficacy of fluticasone propionate/salmeterol hydrofluoroalkane 134a metered-dose-inhaler compared with fluticasone propionate/salmeterol diskus in patients with chronic obstructive pulmonary disease. Open Respir Med J 2010;4:86-91
   PubMedGoogle Scholar
• Tashkin DP, Rennard SI, Martin P, et al. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs 2008;68(14):1975-2000
   PubMed Web of Science ®Google Scholar
• Rennard SI, Tashkin DP, McElhattan J, et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs 2009;69(5):549-65
   PubMed Web of Science ®Google Scholar
• Lyseng-Williamson KA. Budesonide/formoterol pressurized metered-dose inhaler: in chronic obstructive pulmonary disease. Drugs 2009;69(11):1459-70
   PubMed Web of Science ®Google Scholar
• Celli BR, Tashkin DP, Rennard SI, et al. Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD. Respir Med 2011;105(8):1176-88
   Google Scholar
• Sharafkhaneh A, Southard JG, Goldman M, et al. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. Respir Med 2012;106(2):257-68
   PubMed Web of Science ®Google Scholar
• Tashkin DP. Budesonide and formoterol in a single pressurized metered-dose inhaler for treatment of COPD. Expert Rev Respir Med 2010;4(6):703-14
   PubMedGoogle Scholar
• Tashkin DP, Doherty DE, Kerwin E, et al. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials. Int J Chron Obstruct Pulmon Dis 2012;7:73-86
   PubMed Web of Science ®Google Scholar
• Doherty DE, Tashkin DP, Kerwin E, et al. Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD. Int J Chron Obstruct Pulmon Dis 2012;7:57-71
   PubMed Web of Science ®Google Scholar
• Jarvis S, Ind PW, Shiner RJ. Inhaled therapy in elderly COPD patients; time for re-evaluation? Age Ageing 2007;36(2):213-18
   PubMed Web of Science ®Google Scholar
• Molimard M. How to achieve good compliance and adherence with inhalation therapy. Curr Med Res Opin 2005;21(4):S38-7
   Google Scholar
• Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines. ACCP/ACAAI special report. Chest 2005;127(1):335-71
   PubMed Web of Science ®Google Scholar
• Montuschi P. Toward a personalized pharmacotherapy of respiratory diseases. Front Pharmacol 2010;1:131
   PubMed Web of Science ®Google Scholar